POLE-ultramutated endometrial cancer

What changed: POLE-ultramutated endometrial cancer

Cancer page →

Every dated change on the records linked to POLE-ultramutated endometrial cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result2Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordPOLE-ultramutated endometrial cancer
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022MilestonePOLE-ultramutated endometrial cancer
RAINBO programme opens, with POLEmut-BLUE testing de-escalation
A milestone in how this cancer is treated.

2021 · 1

2021MilestonePOLE-ultramutated endometrial cancer
ESGO/ESTRO/ESP guideline allows omission of adjuvant therapy for stage I to II POLE-ultramutated disease
A milestone in how this cancer is treated.

2020 · 1

2020MilestonePORTEC-3
PORTEC-3 molecular analysis: no benefit from chemotherapy in POLE-ultramutated tumours
A milestone in how this cancer is treated.

2018 · 1

2018Trial resultPORTEC-3
PORTEC-3 reported
5-year OS 81.

2017 · 1

2017Trial resultFIRES & SENTOR (sentinel node mapping)
FIRES & SENTOR (sentinel node mapping) reported
Sensitivity 97%, NPV 99.

2015 · 1

2015MilestonePOLE-ultramutated endometrial cancer
ProMisE classifier reproduces the TCGA classes with clinical tests
A milestone in how this cancer is treated.

2013 · 1

2013MilestoneEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
TCGA defines the POLE-ultramutated class of endometrial cancer
A milestone in how this cancer is treated.